破骨细胞释放凋亡小体微小RNA-30a对成骨活性的影响

符义亮; 袁凤来

doi:10.16098/j.issn.0529-1356.2021.04.010

PDF(8947 KB)

解剖学报 ›› 2021, Vol. 52 ›› Issue (4) : 561-566. DOI: 10.16098/j.issn.0529-1356.2021.04.010

细胞和分子生物学

破骨细胞释放凋亡小体微小RNA-30a对成骨活性的影响

符义亮¹ 袁凤来^2*

作者信息 +

Effect of osteoclast-derived apoptotic body microR-30a on osteogenic activity

Author information +

文章历史 +

摘要

目的探讨破骨细胞凋亡释放凋亡小体介导成骨活性的作用。方法通过小鼠（n=10）骨髓单核细胞体外诱导破骨细胞，用抗酒石酸酸性磷酸酶(TRAP)染色和细胞骨架F-actin与DAPI双标免疫荧光鉴定破骨细胞，破骨细胞与小鼠成骨细胞MC-3T3E1共培养体系，DNA片段化ELISA分析破骨细胞凋亡，凋亡小体标志物检测，骨形成标志物Real-time PCR分析，凋亡小体微小RNA (miRNA)表达谱芯片筛查。结果 100 μmol/L 阿伦膦酸钠(ALN) 诱导成熟破骨细胞凋亡，并释放凋亡小体；Western blotting检测表明，ALN诱导凋亡小体特异性表面标志物蛋白表达增强；破骨细胞凋亡小体蛋白C3b表达增高与成骨细胞活性负相关；凋亡小体表达谱芯片筛查提示，miR-30a与骨形成标志物血清碱性磷酸酶(ALP)相关。结论破骨细胞凋亡释放的凋亡小体携带miR-30a抑制成骨细胞活性，凋亡小体可能参与破骨细胞与成骨细胞的对话。

Abstract

Objective To explore that whether apoptotic bodies released by osteoclasts mediate osteogenic activity. Methods The osteoclasts were induced from mouse（n=10）bone marrow monocytes in vitro, and were identified by tartrate resistant acid phosphatase (TRAP) staining, F-actin, and DAPI double labeling immunofluorescence. The Co-culture system of osteoclasts and mouse osteoblasts MC-3T3E1 was established. The apoptosis of osteoclasts was analyzed by DNA fragment ELISA. Immunoblotting of apoptotic body markers was investigated. Real-time PCR analysis of bone formation markers was tested. MiRNA expression profiling of apoptotic body was identisfied. Results Alendronate (ALN) 100 μmol/L induced osteoclast apoptosis and caused apoptotic body release from osteoclasts. The expression of C3b and annexin Ⅴ protein was enhanced by ALN; the expression of C3b in osteoclasts was negatively correlated with the activity of osteoblasts; the microarray screening of apoptotic body showed that miR-30a was correlated with bone formation markers and serum alkaline phosphatase (ALP). Conclusion Osteoclast-derived apoptotic body miR-30a can inhibit the activity of osteoblasts. Apoptotic body may participate in the dialogue between osteoclasts and osteoblasts.

导出引用

符义亮袁凤来. 破骨细胞释放凋亡小体微小RNA-30a对成骨活性的影响[J]. 解剖学报. 2021, 52(4): 561-566 https://doi.org/10.16098/j.issn.0529-1356.2021.04.010

Effect of osteoclast-derived apoptotic body microR-30a on osteogenic activity[J]. Acta Anatomica Sinica. 2021, 52(4): 561-566 https://doi.org/10.16098/j.issn.0529-1356.2021.04.010

中图分类号： Q291

参考文献

［1］ Sleeman A, Clements JN. Abaloparatide: a new pharmacological option for osteoporosis［J］. Am J Health Syst Pharm, 2019, 76(3): 130-135.

［2］ Kalyanaraman H, Ramdani G, Joshua J, et al. A novel, direct NO donor regulates osteoblast and osteoclast functions and increases bone mass in ovariectomized mice［J］. J Bone Miner Res, 2017, 32(1): 46-59.

［3］ Yuan FL, Ye JX, Wang HJ, et al. Effect of Yishen Mic Gu Recipe on bone coversion index betwa-CTX in patients with kidney deficiency osteoporosis［J/OL］. Journal of Clinical Medical Literature, 2017, 4(9): 17825-17827. (in Chinese)

袁凤来，叶俊星，王昊珏，等. 益肾密骨方对肾虚型骨质疏松症患者骨转换指标β-CTX的影响［J/OL］. 临床医药文献电子杂志，2017，4（91）: 17825-17827.

［4］ Cao X. Targeting osteoclast-osteoblast communication［J］. Nat Med, 2011, 17(11): 1344-1346.

［5］ Yuan FL, Ye JX, Li X. Effect of invigorating kidney and sealing bone recipe on bone formation in patients with kidney deficiency osteoporosis［J］. Chinese Journal of Osteoporosis, 2019, 25(8): 1163-1165, 1711. (in Chinese)

袁凤来, 叶俊星, 李霞. 益肾密骨方对肾虚型骨质疏松症患者骨形成的影响［J］. 中国骨质疏松杂志, 2019, 25(8): 1163-1165, 1171.

［6］ Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice［J］. Mayo Clin Proc, 2008, 83(9): 1032-1045.

［7］ Tao H, Yang HY, Yu MCh, et al. Effects of systemic transplantation of allograft adipose-derived stem cells in glucocorticoid-induced osteoporosis rats［J］. Acta Anatomica Sinica, 2011, 42(20): 220-225. (in Chinese)

陶晖, 杨会营, 余美春, 等. 异体脂肪源干细胞移植对糖皮质激素性骨质疏松大鼠的影响［J］. 解剖学报, 2011, 42(2): 220-225.

［8］ Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation［J］. Nature, 2003, 423(6937): 337-342.

［9］ Li C, Yang Z, Li Z, et al. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways［J］. J Bone Miner Res, 2011, 26(3): 644-656.

［10］ Yuan FL, Xu RS, Ye JX, et al. Apoptotic bodies from endplate chondrocytes enhance the oxidative stress-induced mineralization by regulating PPi metabolism［J］. J Cell Mol Med, 2019, 23(5): 3665-3675.

［11］ Liu D, Kou X, Chen C, et al. Circulating apoptotic bodies maintain mesenchymal stem cell homeostasis and ameliorate osteopenia via transferring multiple cellular factors［J］. Cell Res, 2018, 28(9): 918-933.

［12］ Negishi-Koga T, Shinohara M, Komatsu N, et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D［J］. Nat Med, 2011, 17(11): 1473-1480.

［13］ Sun W, Zhao C, Li Y, et al. Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity［J］. Cell Discov, 2016, 2: 16015.

［14］ Li D, Liu J, Guo B, et al. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation［J］. Nat Commun, 2016, 7: 10872.

［15］ Barreca MM, Aliotta E, Geraci F. Extracellular vesicles in multiple sclerosis as possible biomarkers: dream or reality［J］. Adv Exp Med Biol, 2017, 958(1): 1-9.

［16］ Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection［J］. Sci Signal, 2009, 2(100): ra81.

［17］ Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: the mystery of their origin and function［J］. Trends Biochem Sci, 2012, 37(11): 460-465.